6,726 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Callan Capital LLC

Callan Capital LLC acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,726 shares of the company’s stock, valued at approximately $239,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Federated Hermes Inc. increased its holdings in IDEAYA Biosciences by 14.8% in the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock worth $138,185,000 after buying an additional 500,046 shares during the last quarter. Walleye Capital LLC bought a new stake in IDEAYA Biosciences during the third quarter worth approximately $2,265,000. Boone Capital Management LLC boosted its position in IDEAYA Biosciences by 15.0% during the third quarter. Boone Capital Management LLC now owns 570,682 shares of the company’s stock worth $15,397,000 after purchasing an additional 74,249 shares during the period. Barclays PLC boosted its position in IDEAYA Biosciences by 17.8% during the third quarter. Barclays PLC now owns 86,326 shares of the company’s stock worth $2,330,000 after purchasing an additional 13,049 shares during the period. Finally, Eventide Asset Management LLC bought a new stake in IDEAYA Biosciences during the third quarter worth approximately $9,038,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

Insider Activity at IDEAYA Biosciences

In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 23,557 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at $30,870,973.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Briseno Andres Ruiz sold 2,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $46.02, for a total value of $92,040.00. Following the completion of the sale, the insider now directly owns 24,531 shares in the company, valued at $1,128,916.62. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Yujiro S. Hata sold 23,557 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.54, for a total value of $1,072,785.78. Following the completion of the sale, the chief executive officer now owns 677,887 shares of the company’s stock, valued at $30,870,973.98. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on IDYA shares. Leerink Partnrs reaffirmed an “outperform” rating on shares of IDEAYA Biosciences in a research report on Friday, February 23rd. BTIG Research initiated coverage on IDEAYA Biosciences in a research report on Friday, March 8th. They set a “buy” rating and a $55.00 target price for the company. Capital One Financial reissued an “overweight” rating on shares of IDEAYA Biosciences in a research report on Thursday, February 22nd. The Goldman Sachs Group increased their price objective on IDEAYA Biosciences from $36.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Finally, JPMorgan Chase & Co. increased their price objective on IDEAYA Biosciences from $51.00 to $57.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $46.60.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA traded up $1.32 during trading hours on Friday, reaching $39.94. The stock had a trading volume of 619,378 shares, compared to its average volume of 852,284. The business’s fifty day moving average is $43.14 and its two-hundred day moving average is $37.46. The company has a market cap of $2.99 billion, a price-to-earnings ratio of -20.27 and a beta of 0.80. IDEAYA Biosciences, Inc. has a twelve month low of $18.11 and a twelve month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, February 20th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The firm had revenue of $3.90 million during the quarter, compared to analyst estimates of $8.84 million. IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. Sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -2.26 earnings per share for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.